Lapalombella reported that inhibition of XPO1 in CLL cells decreased Mcl‐1 mRNA.29 In contrast, we did not detect a decrease of Mcl‐1 mRNA following KPT‐330 treatment. This evidence concerns the gene XPO1 and B-cell chronic lymphocytic leukemia.